Table 2.
Patient-reported outcomes results from study CA209214 using EQ-5D-3L questionnaire describing the proportion of patients reporting ‘no problem’ for mobility, self-care, activity, pain and anxiety, Functional Assessment of Cancer Therapy-General (FACT-G) mean total score and Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI-19) total score at baseline and at 52 weeks post-baseline.
| Baseline | 52 weeks post-baseline | |||
| Nivolumab+ipilimumab | Sunitinib | Nivolumab+ipilimumab | Sunitinib | |
| EQ-5D-3L | ||||
| Mobility | 75.7% | 76.3% | 83.5% | 71.8% |
| Self-care | 92.3% | 93.1% | 95.0% | 92.2% |
| Activity | 70.3% | 69.4% | 78.5% | 63.1% |
| Pain | 54.0% | 55.3% | 66.9% | 46.6% |
| Anxiety | 61.9% | 59.9% | 76.7% | 77.7% |
| FACT-G | ||||
| Mean | 23.9 | 23.7 | 25.1 | 23.3 |
| FKSI-19 | ||||
| Mean | 61.1 | 60.0 | 65.1 | 61.8 |